Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3 Gastrointestinal 2 Tumor-Agnostic 1 Plasma cell 1 Lymphoid 1 Head & Neck 1

Conditions

Interventions

Cyclophosphamide 886 Rituximab 864 Vincristine 382 Etoposide 381 fludarabine 342 Cytarabine 341 Doxorubicin 340 fludarabine phosphate 319 Methotrexate 310 Dexamethasone 283 Prednisone 282 Lenalidomide 245 Filgrastim 228 Melphalan 200 Peripheral Blood Stem Cell Transplantation 184 Radiotherapy 175 Whole-Body Irradiation 172 Busulfan 165 Mycophenolic Acid 161 venetoclax 158 Bendamustine Hydrochloride 158 Granulocyte Colony-Stimulating Factor 151 Tacrolimus 145 ibrutinib 144 Bortezomib 138 obinutuzumab 125 Gemcitabine 113 Cyclosporine 110 Antilymphocyte Serum 103 Carmustine 100

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Famotidine × Lymphoid × Clear all

NCT03647072 2018-08-27

PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy

Tanta University

Phase 3 Recruiting

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡